Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation | Zendy

Richard M. Stone | Zendy; Sumithra J. Mandrekar | Zendy; Ben L. Sanford | Zendy; Kristina Laumann | Zendy; Susan M. Geyer | Zendy; Clara D. Bloomfield | Zendy; Christian Thiede | Zendy; Thomas W. Prior | Zendy; Konstanze Döhner | Zendy; Guido Marcucci | Zendy; Francesco LoCoco | Zendy; Rebecca B. Klisovic | Zendy; Andrew H. Wei | Zendy; Jorge Sierra | Zendy; Miguel Á. Sanz | Zendy; Joseph Brandwein | Zendy; Théo de Witte | Zendy; Dietger Niederwieser | Zendy; Frederick R. Appelbaum | Zendy; Bruno C. Medeiros | Zendy; Martin S. Tallman | Zendy; Jürgen Krauter | Zendy; Richard F. Schlenk | Zendy; Arnold Ganser | Zendy; Hubert Serve | Zendy; Gerhard Ehninger | Zendy; Sergio Amadori | Zendy; Richard A. Larson | Zendy; Hartmut Döhner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation

Author(s) -

Richard M. Stone,

Sumithra J. Mandrekar,

Ben L. Sanford,

Kristina Laumann,

Susan M. Geyer,

Clara D. Bloomfield,

Christian Thiede,

Thomas W. Prior,

Konstanze Döhner,

Guido Marcucci,

Francesco LoCoco,

Rebecca B. Klisovic,

Andrew H. Wei,

Jorge Sierra,

Miguel Á. Sanz,

Joseph Brandwein,

Théo de Witte,

Dietger Niederwieser,

Frederick R. Appelbaum,

Bruno C. Medeiros,

Martin S. Tallman,

Jürgen Krauter,

Richard F. Schlenk,

Arnold Ganser,

Hubert Serve,

Gerhard Ehninger,

Sergio Amadori,

Richard A. Larson,

Hartmut Döhner

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1614359

Subject(s) - midostaurin , medicine , cytarabine , oncology , myeloid leukemia , chemotherapy regimen , chemotherapy , population , induction chemotherapy , transplantation , gastroenterology , environmental health

Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to standard chemotherapy would prolong overall survival in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research